EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLBEG00000012472
Gene Symbol: GABBR1
3 Cross references
190 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLBEG00000017055
Gene Symbol: GABBR1
3 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2-Like

Ensembl ID : ENSLBEG00000000938
Gene Symbol: LOC109982440
3 Cross references
208 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSLBEG00000028027
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucagon-Like Peptide 1 Receptor

Ensembl ID : ENSLBEG00000015048
Gene Symbol: LOC109986819
2 Cross references
203 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSLBEG00000026667
Gene Symbol: LOC109994498
3 Cross references
205 Possible Orthologues:

Glucokinase

Ensembl ID : ENSLBEG00000023947
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSLBEG00000026624
Gene Symbol: GBA1
3 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSLBEG00000014753
Gene Symbol: GRIA2
3 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSLBEG00000017923
Gene Symbol: GRIA2
1 Cross references
242 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSLBEG00000007978
Gene Symbol: GRIN1
3 Cross references
150 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSLBEG00000002805
Gene Symbol: GRIN2A
1 Cross references
228 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).